New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Allogene Therapeutics, Inc. (ALLO) vs Enanta Pharmaceuticals, Inc. (ENTA)
- Allogene Therapeutics, Inc. ALLO 0.63 −5.97%
- Enanta Pharmaceuticals, Inc. ENTA 7.62 −4.51%
Allogene Therapeutics, Inc. and Enanta Pharmaceuticals, Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Enanta Pharmaceuticals, Inc. are of similar size ($232.7M and $231.1M). Enanta Pharmaceuticals, Inc. grew revenue faster over the last twelve months: −3.56% against −30.4%. Enanta Pharmaceuticals, Inc. has the higher net margin (−108.3% vs −335,973.6%) and the higher return on invested capital (0.00% vs −119.4%). Across the 15 metrics below, Enanta Pharmaceuticals, Inc. leads on 10 and Allogene Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | ALLO | ENTA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 70.18% |
| Operating margin | (342,700.00%) | (99.01%) | 0.00% |
| Net margin | (335,973.56%) | (108.33%) | 0.00% |
| Free cash flow margin | (261,473.56%) | (67.88%) | 0.00% |
| Return on equity | (49.29%) | (94.19%) | (51.58%) |
| Return on assets | (36.69%) | (24.54%) | (45.91%) |
| Return on invested capital | (119.37%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack